RecruitingPhase 2NCT04576793

Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease


Sponsor

Patrick Lao

Enrollment

100 participants

Start Date

Nov 17, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to determine how inflammation is related to other changes in the brain that occur during the progression of Alzheimer's disease. The investigators are also studying how inflammation is related to the symptoms that first occur in patients with Alzheimer's disease (AD). For this reason, the investigators are asking people with different versions of Alzheimer's disease and/or other related dementias to participate. This includes patients with: * Mild Cognitive Impairment * Posterior cortical atrophy - a version of Alzheimer's disease with vision difficulties * Logopenic variant primary progressive aphasia - a version of Alzheimer's disease with language difficulties * Amnestic Alzheimer's disease - a "typical" version of Alzheimer's disease with memory difficulties * The investigators are also enrolling older adults with normal visual, language, and memory function.


Eligibility

Min Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This study uses PET and MRI brain scans to track changes in brain inflammation (microglial activation) in people with different forms of Alzheimer's disease over time. By studying how inflammation changes across different clinical variants of Alzheimer's, researchers hope to better understand disease progression. **You may be eligible if...** - You are 50 years old or older - You either have no cognitive impairment (healthy control) or have been diagnosed with a form of Alzheimer's disease (amnestic, posterior cortical atrophy, or logopenic variant primary progressive aphasia) - Your clinical dementia rating score is appropriate (0 for controls, 0.5 or 1 for patients) - You are fluent in English or Spanish - You are able to attend all required study visits **You may NOT be eligible if...** - You have a brain condition other than Alzheimer's disease (such as stroke or another dementia) - You have serious medical conditions that make study procedures unsafe - You cannot undergo MRI scanning (e.g., pacemaker, severe claustrophobia, or morbid obesity) - You have had significant radiation exposure from other research studies in the past year Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG11C-ER176

11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease. 11C-ER176 will be administered at activity up to 20 millicurie (mCi) per injection.

DRUG18F-MK6240

MK-6240 measures a protein called in the brain. MK-6240 is experimental but has been used in several human studies before and has been proven to accurately measure tau in the brain.

DRUG18F-Florbetaben

Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease. florbetaben measures amyloid in the brain.

PROCEDURELumbar Puncture

Inflammation can also be measured by looking at certain proteins in the spinal fluid. In order to measure these proteins in the spinal fluid, the investigators will perform a lumbar puncture (spinal tap).


Locations(1)

Columbia University Irving Medical Center

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04576793


Related Trials